Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-02-20
2009-11-03
Chernyshev, Olga N (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C424S278100, C424S279100, C424S184100, C424S185100, C424S192100
Reexamination Certificate
active
07612038
ABSTRACT:
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
REFERENCES:
patent: 5340934 (1994-08-01), Termine et al.
patent: 5654270 (1997-08-01), Ruoslahti et al.
patent: 5705609 (1998-01-01), Ruoslahti et al.
patent: 0686397 (1995-04-01), None
patent: WO 93/10808 (1993-10-01), None
Bianco, P. et al. Expression and Localization of the Two Small Proteoglycans, Biglycan and Decorin, in Developing Human Skeletal and Non-Skeletal Tissues.J. Histochem. Cytochem38, 1549-1563 (Nov. 1990).
Bowe, M. A. et al. The Small Lucine-rich Repeat Proteoglycan Biglycan Binds to Dystroglycan and is Unregulated in Dystrophic Muscle.J. Cell. Biol.148, 801-810 (2000).
Chan, Yiu-mo et al. Molecular Organization of Sarcoglycan Complex in Mouse Myotubes in Culture.J. Cell Bio.143, 2033-2044 (Dec. 28, 1998).
Coral-Vasquez, R. et al. Disruption of the Sarcoglycan-Sarcospan Complex in Vascular Smooth Muscle: A Novel Mechanism for Cardiomyopathy and Muscular Dystrophy.Cell98, 465-74 (1999).
Crosbie, Rachelle H. et al. Membrane Targeting and Stabilizatoin of Sarcospan is Mediated by the Sarcoglycan Subcomplex.J. Cell. Biol.145, 159-165 (Apr. 5, 1999).
Ervasti, James M. & Campbell, Kevin P. A Role for the Dystrophin-Glycoprotein Complex as a Transmembrane Linker between Laminin and and Actin.J. Cell Biol.122, 809-823 (Aug. 1993).
Ferri, R. T. et al. A Role for Biglycan in Agrin-Induced Postsynaptic Differentiation.Society for Neuroscience Abstracts26 (2000) [Abstract Only].
Fisher, L. W. et al. Deduced Protein Sequence of Bone Small Proteoglycan I (Biglycan) Shows Homology with Proteoglycan II (Decorin) and Several Nonconnective Tissue Proteins in a Variety of Species.J. Biol. Chem.264, 4571 (1989).
Gee, Stephen H. et al. Dystroglycan-a, a Dystrophin-Associated Glycoprotein, is a Functional Agrin Receptor.Cell77, 675-686 (Jun. 3, 1994).
Hoch, Werner. Formation of the Neuromuscular Junction: Agrin and its unusual receptors.Eur. J. Biochem.265, 1-10 (1999).
Hocking, A. M. et al. Eukaryotic Expression of Recombinant Biglycan.Am. Soc. For Biochem.&Mol. Biol.27, 19571-77 (1996).
Holt, Kathleen H. et al. Functional Rescue of the Sarcoglycan Complex in the BIO 14.6 Hamster Using S-Sarcoglycan Gene Transfer.Mol. Cell1, 841-848 (May 1998).
Ibraghimov-Beslrovanaya et al. Human Dystroglycan: Skeletal Muscle cDNA, Genomic Structure, Origin of Tissue Specific Isoforms and Chromosomal Localization.Hum. Mol. Genet.2, 1651-1657 (1993).
Iozzo, R. Matrix Proteoglycans: From Molecular Design to Cellular Function.Ann. Rev. Biochem.67, 609-652 (1998).
Jarvelainen, Hannu T. et al. Differential Expression of Small Chondroitin/Dermatan Sulfate Proteoglycans, PG-I/Biglycan and PG-II/Decorin, by Vascular Smooth Muscle and Endothelial Cells in Culture.J. Biol. Chem.266, 23274-23281 (Dec. 5, 1991).
Junghans, Ulrich et al. Purification of a Meningeal Cell-derived Chondroitin Sulphate Proteoglycan with Neurotrophic Activity for Brain Neurons and its Identification as Biglycan.Euro. J. Neurosci.7, 2341-2350 (1995).
Khurana, T. S. et al. Interaction of ARIA, a Neuregulin, with the Dystroglycan / Sarcoglycan Complex in Skeletal Muscle.Mol. Cell. Biol.7, 314 (1996).
Krishnan, P. et al. Distinct Secondary Structures of the Leucine-rich Repeat Proteoglycans Decorin and Biglycan.J. Biol. Chem.274, 10945-50 (1999).
Sakamoto, Aiji et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, S-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex.PNAS94, 13873-13878 (Dec. 1997).
Tomoyasu, Hiroshi et al. Identification of haemopoietic biglycan in hyperplastic thymus associated with myasthenia gravis.J. Neuroimmunology89, 59-63 (1998).
Winder, Steven J. The complexities of dystroglycan.Trends in Biochem. Sci.26, 118-124 (2001).
Hasenohrl et al., “Facilitation of learning following injection of the chondroitin sulfate proteoglycan biglycan into the vicinity of the nucleus basalis magnocellularis,”Behavioural Brain Research, 70:59-67 (1995).
Amenta Alison
Bowe Mark A.
Creely Hilliary
Fallon Justin R.
Hagiwara Hiroki
Brown University
Chernyshev Olga N
Cserr Luann
Ropes & Gray LLP
LandOfFree
Biglycan and related therapeutics and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biglycan and related therapeutics and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biglycan and related therapeutics and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4055986